Insider Transactions in Q2 2021 at Biolife Solutions Inc (BLFS)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 15
2021
|
Andrew G Hinson Director |
SELL
Open market or private sale
|
Direct |
2,500
-8.93%
|
$82,500
$33.8 P/Share
|
|
Apr 15
2021
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
6,160
-7.19%
|
$203,280
$33.76 P/Share
|
|
Apr 15
2021
|
Todd Berard Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,160
+6.7%
|
$6,160
$1.64 P/Share
|
|
Apr 15
2021
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-2.77%
|
$165,000
$33.69 P/Share
|
|
Apr 14
2021
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-2.69%
|
$165,000
$33.83 P/Share
|
|
Apr 13
2021
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
10,919
-1.91%
|
$382,165
$35.08 P/Share
|
|
Apr 13
2021
|
Roderick De Greef President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,919
+1.87%
|
$10,919
$1.7 P/Share
|
|
Apr 12
2021
|
Rachel Ellingson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Apr 12
2021
|
Todd Berard Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,362
+2.88%
|
-
|
|
Apr 12
2021
|
Roderick De Greef President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,222
+1.71%
|
-
|
|
Apr 12
2021
|
Michael Rice |
BUY
Grant, award, or other acquisition
|
Direct |
8,487
+3.04%
|
-
|
|
Apr 12
2021
|
Karen A. Foster Chief Quality and Operations |
BUY
Grant, award, or other acquisition
|
Direct |
2,854
+3.73%
|
-
|
|
Apr 12
2021
|
Amy Du Ross Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Apr 12
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,360
+1.57%
|
-
|
|
Apr 08
2021
|
Marcus Schulz Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
224
-0.56%
|
$7,840
$35.77 P/Share
|
|
Apr 08
2021
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
11,461
-4.18%
|
$401,135
$35.32 P/Share
|
|
Apr 08
2021
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
11,461
+4.02%
|
$11,461
$1.64 P/Share
|
|
Apr 01
2021
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
10,149
-3.72%
|
$365,364
$36.53 P/Share
|
|
Apr 01
2021
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
26,154
+8.75%
|
-
|
|
Apr 01
2021
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
3,855
-2.07%
|
$138,780
$36.53 P/Share
|
|
Apr 01
2021
|
Roderick De Greef President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,932
+5.06%
|
-
|
|
Apr 01
2021
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
2,825
-3.53%
|
$101,700
$36.53 P/Share
|
|
Apr 01
2021
|
Todd Berard Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,279
+8.34%
|
-
|
|
Apr 01
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,020
-1.96%
|
$144,720
$36.53 P/Share
|
|
Apr 01
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,358
+4.67%
|
-
|
|
Apr 01
2021
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
3,414
-4.6%
|
$122,904
$36.53 P/Share
|
|
Apr 01
2021
|
Karen A. Foster Chief Quality and Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
8,797
+10.6%
|
-
|